Novartis Pharm Company Profile
What is the competitive landscape for NOVARTIS PHARM
NOVARTIS PHARM has five approved drugs.
There are fourteen US patents protecting NOVARTIS PHARM drugs.
Summary for Novartis Pharm
| US Patents: | 14 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
| Patent Litigation for Novartis Pharm: | See patent lawsuits for Novartis Pharm |
Drugs and US Patents for Novartis Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | AB | RX | Yes | No | 11,135,192 | ⤷ Start Trial | ⤷ Start Trial | |||
| Novartis Pharms | FEMARA | letrozole | TABLET;ORAL | 020726-001 | Jul 25, 1997 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-001 | May 6, 2020 | RX | Yes | No | 10,596,178 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Novartis Pharm | TABRECTA | capmatinib hydrochloride | TABLET;ORAL | 213591-002 | May 6, 2020 | RX | Yes | Yes | 8,461,330 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | AB | RX | Yes | No | 11,058,667 | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novartis Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | 6,465,504 | ⤷ Start Trial |
| Novartis Pharms | FEMARA | letrozole | TABLET;ORAL | 020726-001 | Jul 25, 1997 | 4,978,672 | ⤷ Start Trial |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-002 | Mar 30, 2015 | 6,596,750 | ⤷ Start Trial |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-003 | Mar 30, 2015 | 6,596,750 | ⤷ Start Trial |
| Novartis Pharms Corp | JADENU | deferasirox | TABLET;ORAL | 206910-001 | Mar 30, 2015 | 6,596,750 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2006-03-02 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
| ➤ Subscribe | Tablets for Oral Suspension | 2 mg, 3 mg and 5 mg | ➤ Subscribe | 2016-12-30 |
| ➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
International Patents for Novartis Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ecuador | SP15042897 | ⤷ Start Trial |
| Morocco | 37850 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016012963 | ⤷ Start Trial |
| Mexico | 379279 | ⤷ Start Trial |
| Japan | 2018162255 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novartis Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2340828 | LUC00195 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
| 2340828 | C02340828/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65673 17.09.2015 |
| 2269603 | PA2015041 | Lithuania | ⤷ Start Trial | PRODUCT NAME: EVEROLIMUSUM; REGISTRATION NO/DATE: EU/1/09/538/001, EU/1/09/538/003, EU/1/09/538/004, EU/1/09/538/006-010 20120723 |
| 0663916 | C300154 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EVEROLIMUSUM; NAT. REGISTRATION NO/DATE: RVG 30041RVG 30042RVG 30043RVG 30044RVG 30045RVG 30046 2004100610; FIRST REGISTRATION: 186901869118692186931869418695 2003180718 |
| 2340828 | SPC/GB21/010 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)- BIPHENYL-4-YL)-METHYL)-VALINE)((2R,4S)-5-BIPHENYL -4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER))NA3 X H2O, WHERE; REGISTERED: UK EU/1/15/1058 (NI) 20151123; UK PLGB 00101/1041 20151123; UK PLGB 00101/1042 20151123; UK PLGB 00101/1043 20151123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
